Inpharmatica's Admensa Interactive™ Licensed by Lilly

Inpharmatica Ltd has announced that Eli Lilly and Company has licensed Admensa Interactive, Inpharmatica's suite of predictive drug absorption, distribution, metabolism and excretion models and compound prioritisation tools.

Commenting on the announcement, John Lisle, Chief Executive Officer of Inpharmatica, said, "We are delighted that Lilly, with its significant in-house strength in computational ADME, has chosen AI to augment its discovery support."

"More than ten top pharma and biotech companies have licensed Inpharmatica's innovative suite of predictive models and decision tools for drug discovery."

Admensa Interactive combines predictive models with an intuitive desktop interface combining model output with project data from other sources in an integrated selection and visualisation platform to drive effective decisions on the best compounds for progression against project criteria.

Admensa Interactive is a major component of Inpharmatica's range of gene-to-candidate technologies which integrate biology and chemistry-based drug discovery activities.